Estimados colegas:
Tal y como hemos realizado con congresos previos, a lo largo de la celebración del Congreso Europeo de Cardiología (Barcelona, 30 de Agosto al 3 de Septiembre) comentaremos en nuestro blog los principales resultados de los ensayos clínicos más importantes.
Hot Line: Cardiovascular disease: novel therapies
Domingo, 31 de Agosto
Results of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
Milton PACKER (Dallas, US)
A randomized controlled trial of vagal stimulation for the treatment of systolic heart failure: NEural Cardiac TherApy foR Heart Failure (NECTAR-HF).
Faiez ZANNAD (Vandoeuvre Les Nancy, FR)
Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency
Piotr PONIKOWSKI (Wroclaw, PL)
Cardiac resynchronization therapy with a novel quadripolar lead decreases complications at six months: preliminary results of the MORE-CRT trial
Giuseppe BORIANI (Bologna, IT)
Colchicine for Post- operative Pericardial Effusion: The post-operative pericardial effusion (POPE-2) Study. A multicenter, double-blind, randomized trial
Philippe MEURIN (Villeneuve-St.-Denis, FR)
COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 trial).
Massimo IMAZIO (Torino, IT)
Hot Line: Coronary artery disease and lipids
Domingo, 31 de Agosto
The Stabilization Of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) trial: Primary Results
Michelle O’DONOGHUE (Boston, US)
Ivabradine in patients with stable coronary artery disease without clinical heart failure: The results of SIGNIFY
Kim FOX (London, GB)
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study
Christopher Paul CANNON (Boston, US)
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia not adequately controlled with current lipid-lowering therapy: results of ODYSSEY FH I and FH II studies
Michel FARNIER (Dijon, FR)
Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patients: first results from the ODYSSEY LONG TERM study in 2,341 patients.
Jennifer ROBINSON (Iowa City, US)
The differences of the effects on lipid-lowering actions and glucose metabolisms between rosuvastatin and atorvastatin in Japanese diabetic patients with hyperlipidemia.
Hisao OGAWA (Kumamoto, JP)
Hot Line: Heart failure: devices and interventions
Lunes, 1 de Septiembre
Randomized comparison of a novel, ultrathin strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for percutaneous coronary revascularization
Thomas PILGRIM (Bern, CH)
Autonomic regulation therapy for the improvement of left ventricular function and heart failure symptoms: The ANTHEM-HF Study.
Inder ANAND (Minneapolis, US)
Biventricular pacing for atrIo-ventricular BlOck to Prevent cArdiaC dEsynchronization
Jean-Jacques BLANC (Brest, FR)
Comparison of right ventricular septal pacing and right ventricular pacing in patients receiving a CRT-D
Christophe LECLERCQ (Rennes, FR)
Optimal method and outcomes of catheter ablation of persistent atrial fibrillation: Results of the Prospective, Randomized STAR AF 2 Trial
Atul VERMA (Newmarket, CA)
EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients): a provider perspective on follow-up costs and net financial impact of remote monitoring in six European countries
Hein HEIDBUCHEL (Hasselt, BE)
Hot Line: Myocardial infarction
Lunes, 1 de Septiembre
Complete versus Lesion only PRimary -PCI Trial (CvLPRIT): Treat the infarct related artery only or all lesions
Anthony H GERSHLICK (Leicester, GB)
In-ambulance versus in-cath lab administration of ticagrelor in STEMI patients transferred for primary PCI: the randomized, double-blind ATLANTIC study
Gilles MONTALESCOT (Paris, FR)
The British Heart Foundation Fractional Flow Reserve versus Angiography in Guiding Management to Optimise Outcomes in Non-ST-Segment Elevation Myocardial Infarction
Colin BERRY (Glasgow, GB)
Nitric oxide for inhalation to reduce reperfusion injury in acute st-elevation myocardial infarction
Stefan JANSSENS (Leuven, BE)
Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: Results of the MITOCARE study
Dan ATAR (Oslo, NO)
Hot Line: Coronary artery disease and atrial fibrillation
Martes, 2 de Septiembre / Tuesday, 2nd September
Perioperative statin treatment in cardiac surgery for the prevention of atrial fibrillation and perioperative myocardial damage: the Statin Therapy In Cardiac Surgery (STICS) Trial
Barbara CASADEI (Oxford, GB)
The X-VERT Trial: A comparison of oral rivaroxaban once daily with dose-adjusted Vitamin K Antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion
Riccardo CAPPATO (San Donato Milanese, IT)
Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: A double-blind, randomized, placebo-controlled study
Stine DARKNER (Copenhagen, DK)
Effect of high-intensity statin therapy on atherosclerosis in patients with ST-elevation myocardial infarction: Results of the prospective, longitudinal intravascular ultrasound follow-up study
Lorenz RABER (Bern, CH)
IMPI Steroid Study: A Trial of Adjunctive Prednisolone in Tuberculous Pericarditis
Bongani Mawethu MAYOSI (Cape Town, ZA)